Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8564051 | 1.00 | KCNH2 (0.47) | KCNH2MAPTALDH1A1L3MBTL1RAB9A | |
| Hydrochloric Acid SCHEMBL550146 | 0.98 | KCNH2 (0.46) | KCNH2MAPTALDH1A1L3MBTL1RAB9A | |
| SCHEMBL13610184 | 0.84 | CHRM2 (0.47) | KCNH2ALDH1A1KDM4ETSHRPOLB | |
| SCHEMBL6629846 | 0.83 | KCNH2 (0.50) | KCNH2MAPTALDH1A1 | |
| SCHEMBL27458040 | 0.82 | KCNH2 (0.46) | KCNH2ALDH1A1L3MBTL1TSHR | |
| Hydrochloric Acid SCHEMBL2258244 | 0.81 | KCNH2 (0.49) | KCNH2MAPTALDH1A1 | |
| SCHEMBL17348461 | 0.81 | KDM4E (0.50) | MAPTALDH1A1RAB9AKDM4ETSHR | |
| SCHEMBL27528632 | 0.81 | KCNH2 (0.47) | KCNH2MAPTALDH1A1KDM4ETSHR | |
| SCHEMBL4738304 | 0.80 | ALDH1A1 (0.42) | MAPTALDH1A1KDM4EPOLB | |
| SCHEMBL5576688 | 0.79 | EPHX2 (0.49) | KCNH2ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225223-B1 | ORGANIC COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2017-01-11 | — | — | EP | disclosed |
| EP-2225227-B1 | 1',3'-Dihydrospiro[imidazolidin-4,2'-inden]-2,5-diones and 1,3-dihydrospiro[inden-2,3']-pyrroles as CGRP antagonists | BOEHRINGER INGELHEIM INT (DE) | 2015-08-26 | — | — | EP | disclosed |
| US-8829006-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-09 | — | — | US | disclosed |
| US-8110575-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| US-8110575-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| US-8110575-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| US-20110195954-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-11 | — | — | US | disclosed |
| US-20110195954-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-11 | — | — | US | disclosed |
| US-20110021500-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021500-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-1996591-A1 | SPIROINDOLINONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| EP-1476151-B1 | 1-ARYLSULFONYL-3-SUBSTITUED INDOLE AND INDOLINE DERIVATES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ORGANON NV (NL) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007104714-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-20 | — | — | WO | disclosed |
| CN-1729174-A | Synthesis of amines and intermediates for the synthesis thereof | CIBA SC HOLDING AG (CH) | 2006-02-01 | — | — | CN | disclosed |
| US-20050154023-A1 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | MERCK SHARP & DOHME B.V. (NL) | 2005-07-14 | — | — | US | disclosed |
| EP-1476151-A1 | 1-ARYLSULFONYL-3-SUBSTITUED INDOLE AND INDOLINE DERIVATES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Akzo Nobel N.V. (NL) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068220-A1 | 1-ARYLSULFONYL-3-SUBSTITUTED INDOLE AND INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | AKZO NOBEL N.V. (NL) | 2003-08-21 | — | — | WO | disclosed |
| EP-0287196-B1 | Indole derivatives, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1994-11-23 | — | — | EP | disclosed |
| US-4920127-A | TREATMENT OF MIGRAINE, TRIGEMINAL NEURALGIA | BEECHAM GROUP P.L.C. (GB) | 1990-04-24 | — | — | US | disclosed |
| EP-0287196-A1 | Indole derivatives, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1988-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021500-A1 | NOVEL COMPOUNDS | CALCRL, CALCR, CALCA | KCNH2 386/4885MAPT 797/4885ALDH1A1 1445/4885 |
| US-20050154023-A1 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | TPH1, HTR1A, HTR1D | KCNH2 718/4885MAPT 68/4885ALDH1A1 1048/4885 |
| US-20110195954-A1 | NOVEL COMPOUNDS | CALCRL, CALCR, CALCA | KCNH2 394/4885MAPT 615/4885ALDH1A1 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.